<DOC>
	<DOCNO>NCT00650390</DOCNO>
	<brief_summary>The study explore efficacy adalimumab subject previously treat infliximab fail infliximab treatment due lack efficacy intolerance . To explore safety adalimumab subject previously treat infliximab .</brief_summary>
	<brief_title>Open Label Study Assess Efficacy Safety Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Males female &gt; = 18 year age ACR criterion RA diagnosis least 6 month Active RA define DAS 28 &gt; 3.2 study entry Unsatisfactory response , loss response intolerance prior infliximab treatment A negative pregnancy test female childbearing potential Patient previous treatment cyclophosphamide chlorambucil Treatment within last 8 week infliximab Prior treatment one DMARD DMARD combination follow infliximab treatment Prior treatment biologics ( Investigational Commercial ) RA therapy infliximab History cancer , successfully treat squamous cell basal cell carcinoma lymphoproliferative disease Prior treatment total lymphoid irradiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>